Form 4: Nutex Health Director Receives RSU Grant, Form 4 Filed Late

Nutex Health director Cheryl Yvonne Grenas was granted 603 Restricted Stock Units (RSUs) on July 14, 2025, which vest on July 14, 2026, with the Form 4 filing occurring significantly after the transaction date.

Summary

• Cheryl Yvonne Grenas, a Director of Nutex Health, Inc. (NUTX), was granted 603 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting.
• The grant date for these RSUs was July 14, 2025.
• The RSUs are scheduled to vest 100% on July 14, 2026.
• A pro-rata vesting provision applies if the Reporting Person leaves service without cause during the vesting period.
• The Form 4 reporting this transaction was filed on February 9, 2026, which is significantly after the two-business-day deadline for reporting insider transactions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with a low-moderate sentiment. While the RSU grant itself is a positive for director alignment, the significant delay in filing the Form 4 raises concerns about the company's internal controls and SEC compliance.

Positives

• The RSU grant aligns the director's interests with those of shareholders by providing equity-based compensation.
• The grant serves as a retention mechanism for a key board member.

Negatives

• The Form 4 was filed on February 9, 2026, reporting a transaction that occurred on July 14, 2025, indicating a significant delay in SEC compliance.
• This late filing suggests a potential lapse in internal controls or oversight regarding timely insider transaction reporting.

Risks

• Compliance risk due to the significant delay in filing the Form 4, which is a violation of Section 16(a) of the Securities Exchange Act of 1934.
• Potential forfeiture of unvested RSUs if the director's service with the company terminates for cause before the vesting date.

Future Outlook

The 603 Restricted Stock Units granted to Director Cheryl Yvonne Grenas are expected to vest fully on July 14, 2026, contingent on her continued service with the company or pro-rata vesting under specific conditions.

Industry Context

StockSavvy.ai notes that RSU grants are a standard component of director compensation packages across various industries, designed to align leadership incentives with long-term shareholder value. However, timely filing of Form 4s is a fundamental regulatory requirement for all public companies, and significant delays are uncommon and raise compliance questions.

Comparison to Industry Standards

• The grant of RSUs as director compensation is consistent with common industry practices for attracting and retaining qualified board members.
• The delayed filing of this Form 4, occurring more than six months after the transaction date, falls significantly below the industry standard for SEC compliance, which mandates reporting within two business days.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the late filing negatively, potentially questioning the company's governance and compliance standards, despite the small size of the RSU grant.
• Regulatory Authorities: The late filing could attract attention from the SEC regarding compliance with reporting requirements.

Next Steps

• The 603 RSUs are scheduled to vest on July 14, 2026, at which point they will convert into shares of common stock.

Key Dates

Recommendation

The RSU grant itself is a routine compensation event and not inherently price-sensitive. However, the significant delay in filing the Form 4 is a compliance concern. Given the small number of shares involved, the direct impact on the stock price from this specific transaction is minimal, but the governance implications warrant a 'hold' rather than a 'buy' until clarity on compliance procedures is established.

Keywords

Nutex Health, NUTX, Restricted Stock Units, RSU grant, Director compensation, Insider transaction, SEC Form 4, Corporate governance, Equity compensation